Mastodon

Framixa (Spray) Instructions for Use

Marketing Authorization Holder

Iris, LLC (Russia)

Manufactured By

YUGPHARM, LLC (Russia)

ATC Code

R01AX08 (Framycetin)

Active Substance

Framycetin (Rec.INN WHO registered)

Dosage Form

Bottle Rx Icon Framixa Nasal spray 1.25%

Dosage Form, Packaging, and Composition

Nasal spray

1 ml
Framycetin sulfate 12.5 mg

15 ml – bottles – cardboard packs – By prescription

Clinical-Pharmacological Group

Antibacterial drug for topical use in ENT practice

Pharmacotherapeutic Group

Drugs for the treatment of nasal diseases; decongestants and other preparations for topical use; other drugs for the treatment of nasal diseases

Pharmacological Action

An antibiotic from the aminoglycoside group with a broad spectrum of action for topical use in otorhinolaryngology. It acts bactericidally, damages the cytoplasmic membrane, disrupts the flow of metabolites inside the cell and causes rapid death of microorganisms.

It is active against most gram-positive and gram-negative bacteria: Staphylococcus aureus, Staphylococcus spp. (including strains resistant to other antibiotics), some strains of Streptococcus spp., Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., Haemophilus influenzae, Salmonella spp., Shigella spp., Enterobacter spp., Proteus spp., Serratia marcescens, Pasteurella spp., Vibrio spp., Borrelia, Leptospira spp., Mycobacterium tuberculosis (including strains resistant to streptomycin), which cause the development of infectious processes in the upper respiratory tract.

Treponema spp., some strains of Streptococcus spp., and anaerobic microorganisms are resistant to framycetin.

Pharmacokinetics

When applied topically, it has low systemic absorption.

Indications

As part of combination therapy for infectious and inflammatory diseases of the upper respiratory tract, including: rhinitis, rhinopharyngitis, sinusitis (in the absence of septal damage). Prevention and treatment of inflammatory processes after surgical interventions.

ICD codes

ICD-10 code Indication
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J02 Acute pharyngitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
Z29.2 Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes)
ICD-11 code Indication
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
QC05.Y Other specified prophylactic measures

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer intranasally only. Clear nasal passages prior to application.

For adults and children: administer one spray into each nostril. The frequency of administration is three to six times per day.

Adhere strictly to a maximum treatment duration of seven days. Do not exceed this duration.

For postoperative prophylaxis and treatment: initiate use as directed by a physician following the surgical procedure.

Discontinue use immediately upon resolution of infectious and inflammatory symptoms. Do not use for prolonged periods.

If no clinical improvement is observed within three to four days, reevaluate the diagnosis and treatment strategy.

Avoid contact with eyes. If contact occurs, rinse thoroughly with water.

Adverse Reactions

Possible: allergic reactions.

Contraindications

Hypersensitivity to antibiotics of the aminoglycoside group; pregnancy, breastfeeding period.

Framycetin should not be used for washing the paranasal sinuses.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Pediatric Use

Can be used in children according to indications, in recommended doses.

Special Precautions

During treatment, the appearance of resistant strains of microorganisms is possible.

Aminoglycoside antibiotics can cause reversible, partial or complete deafness and have a nephrotoxic effect when used systemically and when applied topically to open wounds or damaged skin. These effects are dose-dependent and are enhanced in cases of impaired liver or kidney function. The risk of their occurrence should be taken into account in case of topical application of high doses of the drug in children. Therapy should not be continued after the symptoms disappear.

Framycetin should not be used simultaneously with other antibiotics that have ototoxic and nephrotoxic effects ( streptomycin, monomycin, kanamycin, gentamicin).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS